A novel Temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo

March 2015

Cancer Letters 2015, 358:144.


This report on compound NEO212 demonstrates its cancer therapeutic potency in mouse models of aggressive melanoma. In the clinic, melanoma patients frequently do not respond well to treatment with temozolomide. One of the reasons is the presence in tumor cells of a resistance protein called MGMT, which neutralizes the cell-killing potency of temozolomide. In this study, we demonstrate that NEO212 not only kills regular melanoma cells, but also those that harbor the MGMT protein that protects them from killing by temozolomide.

Comments are closed.